Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Acrivon Therapeutics Inc

ACRV ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$1.95

▲ +5.41%

Market Cap $83.56M · Vol 171.74K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$83.56M

Micro Cap

Div Yield

N/A

EPS Growth

+6.25%

YoY

RSI (14)

76.71

Momentum

Beta

1.97

vs Market

52W High

$3.54

44.92% below

52W Low

$1.27

53.54% above

Volume

171.74K

Avg 98.98K

P/B

0.68

Price-to-book

ROE

-53.86%

Return on equity

Free Float

84.35%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Acrivon Therapeutics Inc (ACRV) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ACRV pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+12.72%

-8.45%

+1.56%

+19.63%

YTD

-19.09%

+40.29%

-83.36%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-77,905,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-53.86%
ROA · ROIC	-47.75% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	0.68
P/FCF	N/A
EPS Growth	+6.25%
Outstanding Shares	42.85M

Technical Indicators

50-Day SMA	$1.67
200-Day SMA	$1.85
RSI (14)	76.71
Beta	1.97
52-Week High	$3.54
52-Week Low	$1.27

Volume Today	171.74K
Avg Daily Volume (30D)	98.98K
Relative Volume	1.74x
Volatility (10D)	41.19
Volatility (30D)	73.84
Free Float	84.35%

Analyst Consensus

BUY

Current Price $1.95

Mean Target $11.50

52W Low$1.27 52W High$3.54

Current

Target

$1.27 $3.54

Current Analyst target

+489.74% upside potential · 8 analysts

Identifiers

ExchangeNasdaq

FIGIBBG011RWR2R3

ISINUS0048901096

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 13, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision oncology medicines. It uses its precision Generative Phosphoproteomics platform, Acrivon Predictive Precision Proteomics (AP3), to develop its pipeline of oncology drug candidates. Its lead candidate, ACR-368, is a selective small molecule inhibitor which targets CHK1 and CHK2 at sub single-digit nM and single-digit nM potency in intact cells, respectively, in a registrational Phase II trial across multiple solid tumor types. Using its AP3 platform, it has developed a predictive OncoSignature test for ACR-368, called ACR-368 OncoSignature, that can predict patient response to ACR-368 monotherapy and therefore improve the clinical overall response rate (ORR) and has the potential to enable drug development. Its preclinical program, ACR-2316, is advancing in investigational new drug-enabling studies. It is a novel, dual WEE1 and PKMYT1 inhibitor small molecule development candidate.